Cargando…
Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation
Dyslipidemia is a frequent side effect associated with nilotinib treatment. Patients with chronic myeloid leukemia (CML) under treatment with nilotinib who develop dyslipidemia have been shown to have a higher risk of presenting atherosclerotic cardiovascular disease (ACVD). Therapeutic discontinuat...
Autores principales: | Roa-Chamorro, Ricardo, Puerta-Puerta, José Manuel, Torres-Quintero, Lucía, Jaén-Águila, Fernando, González-Bustos, Pablo, Rodríguez-Gil, Miguel Ángel, Mediavilla-García, Juan Diego |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361990/ https://www.ncbi.nlm.nih.gov/pubmed/37479802 http://dx.doi.org/10.1038/s41598-023-39057-x |
Ejemplares similares
-
Arterial hypertension assessment in a population with chronic myeloid leukemia
por: Roa-Chamorro, Ricardo, et al.
Publicado: (2021) -
Mathematical Model for Low Density Lipoprotein (LDL) Endocytosis by Hepatocytes
por: Wattis, J. A. D., et al.
Publicado: (2008) -
Native High Density Lipoproteins (HDL) Interfere with Platelet Activation Induced by Oxidized Low Density Lipoproteins (OxLDL)
por: Badrnya, Sigrun, et al.
Publicado: (2013) -
Low-Density Lipoprotein (LDL)-Antioxidant Biflavonoids from Garcinia madruno
por: Osorio, Edison, et al.
Publicado: (2013) -
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report
por: Caocci, Giovanni, et al.
Publicado: (2014)